Home » Stocks » Aprea Therapeutics

Aprea Therapeutics, Inc. (APRE)

Stock Price: $31.46 USD -1.38 (-4.20%)
Updated Jul 9, 2020 12:15 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 662.39M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 20.99M
EPS (ttm) -26.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 9, 2020
Last Price $31.46
Previous Close $32.84
Change ($) -1.38
Change (%) -4.20%
Day's Open 32.85
Day's Range 30.51 - 33.59
Day's Volume 60,692
52-Week Range 15.10 - 53.11

More Stats

Market Cap 662.39M
Enterprise Value 540.10M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 20.99M
Float 12.11M
EPS (basic) n/a
EPS (diluted) -26.67
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 763,234
Short Ratio 3.92
Short % of Float 13.14%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.50
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 122.29M
Net Cash / Share 5.81
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -18.50%
ROE -38.95%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 1
Overweight 1
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$39.00*
(23.97% upside)
Low
30.0
Current: 31.46
High
45.0
Target: 39.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue---
Operating Income-29.54-16.49-15.85
Net Income-28.06-15.53-15.19
Shares Outstanding6.001.151.15
Earnings Per Share-4.67-13.45-13.17
Operating Cash Flow-26.71-15.25-14.00
Capital Expenditures-0.03--
Free Cash Flow-26.74-15.25-14.00
Cash & Equivalents13065.6824.40
Total Debt0.30--
Net Cash / Debt13065.6824.40
Assets13466.0224.76
Liabilities9.364.874.30
Book Value124-51.44-35.77
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aprea Therapeutics, Inc.
Country United States
Employees 13
CEO Christian S. Schade

Stock Information

Ticker Symbol APRE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: APRE

Description

Aprea Therapeutics, Inc., a biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate is APR-246, a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. The company was founded in 2006 and is headquartered in Boston, Massachusetts.